Alzheimer's Disease
Filter News
Found 821 articles
-
Cyclo Therapeutics to Hold Call for Patients and Investors Wednesday, May 20 at 4:30 pm EDT
5/19/2020
Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that it will hold a call for investors and the NPC community on Wednesday, May 20, 2020 at 4:30 pm EDT. “We look forward to speaking to the patient and investor communities about the data from our comp
-
Todos Medical Announces First Commercial Sale of COVID-19 Antibody Tests
5/18/2020
Sub-distributor has network of state and local government clients seeking testing solutions Return to Church program being initiated in Orlando, Fla. area REHOVOT, Israel, SINGAPORE and NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (OTCQB: TOMDF) , an in vitro diagnostics company focused on the distribution of a comprehensive suite of solutions for the screening and diagnosis of COVID-19 and the development of blood tests for the early detection of
-
C2N Diagnostics Receives $20M Program-Related Investment from GHR Foundation to Bring Alzheimer’s Blood Test to the Clinic
5/14/2020
C 2 N Diagnostics Receives $20M Program-Related Investment from GHR Foundation to Bring Alzheimer’s Blood Test to the Clinic
-
Cyclo Therapeutics Reports Publication of International Patent Application for Treatment of Alzheimer’s Disease
5/14/2020
Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that the international patent application titled “Methods for Treating Alzheimer’s Disease” was published as International Publication Number: WO 2020/092107 Al . The patent application describes treating
-
Cortexyme Publishes Data on P. Gingivalis Ability to Infect Neurons, Drive Alzheimer’s-Like Pathology in the Journal of Alzheimer’s Disease
5/6/2020
May 6, 2020 12:30 UTC Cortexyme Publishes Data on P. Gingivalis Ability to Infect Neurons, Drive Alzheimer’s-Like Pathology in the Journal of Alzheimer’s Disease SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s (AD) and other degenerative diseases, today announced the pu
-
Green Valley Pharmaceutical and MMS Holdings Collaborate to Gain FDA Approval to Begin Clinical Trials for the First Alzheimer’s Drug in 17 Years
5/5/2020
MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO – announced that a successful collaboration with Shanghai-based Green Valley Pharmaceutical Co. (Green Valley) resulted in gaining U.S. Food & Drug Administration (FDA) approval of an Investigational New Drug (IND) application for the GV-971 international multi-center Phase 3 clinical study in the treatment of patients with Alzheimer’s disease.
-
Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator Announces First Digital Biomarker Research Award and Data Sharing Platform
4/29/2020
- Digital biomarker awards support technology solutions for early detection of Alzheimer's and related dementias - Data platform enables researchers using digital tools to share their findings for benchmarking, analysis and use across research projects - ADDF's Diagnostics Accelerator has $50 million in commitments from leading philanthropists Leonard A. Lauder, Bill Gates, Jeff Bezos and MacKenzie Bezos, the Dolby family, the Charles and Helen Schwab Foundation,
-
About 70% of AD patients have symptoms of agitation, which is marked by emotional distress, aggressive behaviors, disruptive irritability and loss of inhibition.
-
Cyclo Therapeutics Closes $2.0 Million Private Placement
4/27/2020
Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that it has closed a private placement of its securities with a group of accredited investors that included several directors of the Company and members of management. Investors in the private placement purch
-
Cortexyme Presents Data Supporting Role of P. Gingivalis in Alzheimer’s Pathology at Advances in Alzheimer’s and Parkinson’s Therapies Virtual Focus Meeting 2020
4/2/2020
-- New results demonstrate P. gingivalis’ ability to infect neurons and cause characteristic Alzheimer’s pathology
-
Bio-Pharm Solutions Expands from Epilepsy to Neurodegenerative Diseases Aiming for IPO
3/26/2020
The oral medication for Infantile spasms (IS) is in phase 2 clinical trials in Korea and the US, and the IV medication for Status epilepticus (SE) is in phase 1 clinical trials in the US. The company has established new pipelines, including Alzheimer's Disease, and is set to embark on clinical trials (phase 2) by expanding R&D through an IPO [26-March-2020] SUWON, S
-
Cassava Sciences Announces Initiation of an Open-Label Study to Evaluate PTI-125 in Patients with Alzheimer’s DiseaseApproximately 100 Study Participants Will Receive PTI-125 For 12 Months
3/25/2020
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the initiation of an open-label extension study to evaluate PTI-125 in patients with Alzheimer’s disease. The Company’s lead investigational drug, PTI-125, seeks to improve both neurodegeneration and neuroinflammation in patients with Alzheimer’s disease. “We believe the ability of our drug to improve multiple function
-
Cognition Therapeutics Announces Publication Analyzing Biomarkers of Synapse Damage or Loss to Support Future Therapeutic Development Efforts in Alzheimer's Disease
3/17/2020
Cognition Therapeutics, Inc. , a clinical-stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced the publication of an article titled, The Clinical Promise of Biomarkers of Synapse Damage or Loss in Alzheimer’s Disease , which reviews the foundational role of synapses in cognitive function and discusses available and experimental b
-
Cortexyme Announces Gain Trial in Alzheimer’s Disease Has Reached Enrollment Milestone of 300 Patients
3/16/2020
Cortexyme, Inc. (Nasdaq: CRTX) today announced that enrollment in its GAIN Trial for Alzheimer’s disease has reached 300 patients toward the study's previously announced enrollment
-
Primary Care Physicians on the Front Lines of Diagnosing and Providing Alzheimer's and Dementia Care: Half Say Medical Profession Not Prepared to Meet Expected Increase in Demands
3/11/2020
- Report provides latest Alzheimer's prevalence, incidence, mortality and costs of care data -
-
New Roskamp Institute Clinical Research Shows Promise of Drug yo Slow Early-stage Alzheimer's Disease
3/6/2020
New data from a clinical trial of Alzheimer's Disease using a drug called Nilvadipine identified by researchers at the Roskamp Institute show that patients with very mild (very early stage) Alzheimer's disease show less cognitive decline over an 18-month period than placebo-treated patients. On the key clinical measure of memory, the
-
Cortexyme Provides Regulatory Update for COR388 Development Program in Alzheimer’s Disease
2/13/2020
Cortexyme, Inc.. (Nasdaq: CRTX) today provided an update on its clinical development plans for COR388, the company’s lead investigational medicine in development for mild to moderate Alzheimer’s disease (AD).
-
Oligomerix Presents Preclinical Data at TAU2020 Global Conference for Small Molecule Inhibitor of Tau Self-Association
2/12/2020
OLIGOMERIX., a privately held company pioneering the development of small molecule therapeutics targeting tau for Alzheimer’s disease (AD) and related neurodegenerative disorders, announced that the company presented efficacy data for its lead program, a small molecule inhibitor of tau self-association, in two preclinical models of tauopathy.
-
DIAN-TU-001 is a Phase II/III trial that tested two therapies compared to placebo, Genentech and Roche’s gantenerumab and Eli Lilly and Company’s solanezumab.
-
Investigators at the Case Western University School of Medicine identified a previously unknown gene and the resultant protein that may potentially slow the progress of Alzheimer’s disease.